期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 152, 期 2, 页码 155-163出版社
WILEY
DOI: 10.1111/j.1365-2141.2010.08491.x
关键词
apoptosis; Multiple-Myeloma; Immunoproteasome
类别
资金
- NIH [SPORE-P50100707, PO1-CA078378, RO1CA050947]
- MRF funds
- NATIONAL CANCER INSTITUTE [P01CA078378, P01CA155258, R01CA050947, P50CA100707] Funding Source: NIH RePORTER
P>PR-924 is an LMP-7-selective tripeptide epoxyketone proteasome inhibitor that covalently modifies proteasomal N-terminal threonine active sites. In the present study, we show that PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cell lines and primary patient MM cells, without significantly affecting normal peripheral blood mononuclear cells. PR-924-induced apoptosis in MM cells is associated with activation of caspase-3, caspase-8, caspase-9, BID, PARP and cytochrome-c release. In vivo administration of PR-924 inhibits tumour growth in human plasmacytoma xenografts. Results from SCID-hu model show a significant reduction in the shIL-6R levels in mice treated with PR-924 versus vehicle-control. PR-924 treatment was well tolerated as evidenced by the lack of weight loss. Importantly, treatment of tumour-bearing mice with PR-924, but not vehicle alone, prolonged survival. Our preclinical findings therefore validate immunoproteasome LMP-7 subunit as a novel therapeutic target in MM.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据